Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO EBITDA Margin

EBITDA as a percentage of revenue.

Knight Therapeutics Inc.TSX: GUD.TO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 18.0%

EBITDA Margin was 18.0% in Q1 FY2026, up 3.3 pp from a year earlier. On a trailing-twelve-month basis it was 12.8%, down 5.8 pp year over year. Over 3 fiscal years it widened by 3.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 17.2% for the fiscal year ending Dec 2026, up from 12.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
18.0%+2.0 pp QoQ
Last fiscal yearDec 2025
12.1%-5.3 pp YoY
LTMMar 2026
12.8%-5.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.3 pp+15.7 pp+12.3 pp
1 year-5.3 pp+5.2 pp+10.4 pp
3 years+3.5 pp+13.1 pp+9.6 pp
5 years+15.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
12.1%
Year-over-year change
-5.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • GUD.TO's LTM Mar 2026 EBITDA Margin of 12.8% is the 5th highest of the 8 companies compared; the peer median is 19.0%.
  • Its year-over-year change of -5.8 pp is the 6th highest of 8, against a peer median of +3.9 pp.
  • Over three fiscal years its change of +3.5 pp compares with a peer median of +30.9 pp.
GUD.TO Competitors Peer median
EBITDA Margin for GUD.TO and competitors
Company Period LTM level YoY 3-year change
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 202649.3% +16.9 pp-11.3 pp
TSND.TOTerrAscend Corp.LTM Mar 202623.1% +19.6 pp+126.3 pp
VHI.TOVitalhub Corp.LTM Mar 202620.3% +3.9 pp+8.2 pp
KSI.TOKneat.com, Inc.LTM Mar 202619.0% -5.2 pp+22.3 pp
GUD.TOKnight Therapeutics Inc.LTM Mar 202612.8% -5.8 pp+3.5 pp
ACB.TOAurora Cannabis Inc.LTM Mar 20263.1% -11.9 pp+39.6 pp
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-14.9% -18.5 pp—
WEED.TOCanopy Growth CorporationLTM Mar 2026-20.4% +157.8 pp+798.1 pp
Peer median (excluding GUD.TO) 19.0%+3.9 pp+30.9 pp

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.48M293.56M328.2M371.3M450.09M
Cost of Revenue128.07M155.5M175.55M196.9M299.35M
Gross Profit115.41M138.06M152.65M174.41M150.74M
Gross Margin47.4%47.0%46.5%47.0%33.5%
Research & Development12.69M14.76M17.55M23.3M28.98M
Selling, General & Admin74.38M88.62M83.69M99.35M123.96M
Operating Expenses128.24M155.12M155.54M167.01M152.94M
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
EBITDA42.59M25.26M40.9M64.38M54.37M
EBITDA Margin17.5%8.6%12.5%17.3%12.1%
Operating Income(5.32M)(2.4M)(2.89M)7.4M(2.2M)
Operating Margin-2.2%-0.8%-0.9%2.0%-0.5%
Interest Income7.38M10.63M12.58M10.41M6.21M
Interest Expense3.62M6.6M12.49M9.22M10.42M
Other Income / Expenses19.52M(2.92M)(19.1M)(5.35M)(4.5M)
Income Before Tax6.69M(43.96M)(21.99M)2.05M(6.7M)
Pre-Tax Margin2.7%-15.0%-6.7%0.6%-1.5%
Income Tax Expense(8.99M)(14.07M)(5.15M)(2.28M)(1.33M)
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Net Margin6.4%-10.2%-5.1%1.2%-1.2%
EPS (Basic)0.13(0.26)(0.16)0.04(0.05)
EPS (Diluted)0.13(0.26)(0.16)0.04(0.05)
Weighted Avg Shares124.48M114.89M107.47M101.04M99.57M
Weighted Avg Shares (Diluted)124.52M114.89M107.47M101.44M99.57M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.